Eandtnews

August 17, 2026 — VivoSim Labs, Inc. (NASDAQ: VIVS) is gaining investor attention as its 3D human tissue models, artificial intelligence and New Approach Methodologies (NAMs) target one of pharmaceutical development’s biggest challenges: identifying drug toxicity before costly clinical trials.

The opportunity comes as the U.S. Food and Drug Administration (FDA) advances initiatives supporting human-relevant alternatives to traditional animal testing. In 2026, the FDA issued draft guidance addressing the validation and use of NAM technologies, including organoids, spheroids, organs-on-chips and computational models, creating a potentially favorable regulatory environment for companies developing advanced preclinical testing technologies.

VivoSim reported that its NAMkind™ Liver model achieved 91% predictive accuracy, 90% sensitivity and 95% specificity across a 92-compound clinical small-molecule dataset under repeat-dose conditions. The company’s VitroSense™ AI platform, trained using data from its human intestinal models, separately achieved a reported 96% predictive accuracy in its training dataset for potential drug-induced diarrhea.

Alongside VivoSim Labs, Inc. (NASDAQ: VIVS), investors are watching several other stocks seeing active early trading, including INVO Fertility, Inc. (NASDAQ: IVF), OSR Health, Inc. (NASDAQ: OSRH) and IGC Pharma, Inc. (NYSE: IGC), with fresh company news adding to investor attention today.

VivoSim is also targeting the growing antibody-drug conjugate (ADC) market, where its liver and intestinal models are being evaluated for their ability to identify toxicity associated with ADC payloads, linkers and other components.

Commercialization is beginning to advance. VivoSim recently announced its first commercial NAMkind sales in mainland China, moving the platform from scientific validation toward paid pharmaceutical applications.

The company has also strengthened its financial position, reporting approximately $10.1 million in cash as of August 3, 2026, following a $5 million milestone payment from Eli Lilly and Company (NYSE: LLY), additional escrow proceeds and a July financing. VivoSim has reiterated guidance for 500%+ revenue growth in fiscal 2027, driven by its expansion of NAM-based contract research services to pharmaceutical companies.

For investors following VIVS stock, AI biotech, drug toxicity testing, 3D human tissue models, FDA animal-testing alternatives, ADC drug development and New Approach Methodologies, the key question is increasingly whether VivoSim can turn predictive human biology into a scalable pharmaceutical research business.

About VivoSim Labs

VivoSim Labs, Inc. (NASDAQ: VIVS) provides pharmaceutical and biotechnology companies with 3D human liver and intestinal tissue models for drug testing and toxicology using New Approach Methodologies (NAMs).

Disclaimers: The Private Securities Litigation Reform Act of 1995 provides investors with a safe harbor with regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, assumptions, objectives, goals, and assumptions about future events or performance are not statements of historical fact and may be forward looking statements. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties that could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements, indicating certain actions & quotes; may, could or might occur Understand there is no guarantee past performance is indicative of future results. Investing in micro-cap or growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investor’s investment may be lost or due to the speculative nature of the companies profiled. TheStreetReports (TSR) is responsible for the production and distribution of this content.”TSR” is not operated by a licensed broker, a dealer, or a registered investment advisor. It should be expressly understood that under no circumstances does any information published herein represent a recommendation to buy or sell a security. “TSR” authors, contributors, or its agents, may be compensated for preparing research, video graphics, podcasts and editorial content. “TSR” has not been compensated to produce content related to “Any Companies” appearing herein. As part of that content, readers, subscribers, and everyone viewing this content are expected to read the full disclaimer in our website.

Media Contact
Company Name: The Street Reports
Contact Person: Editor
Email: Send Email
Country: United States
Website: http://www.thestreetreports.com